Advise Taking "Flozins" in the Morning
Jardiance (jar-DEE-ans, empagliflozin) will be the third SGLT2 inhibitor...after Invokana (canagliflozin) and Farxiga (dapagliflozin).
These "flozins" increase glucose excretion by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.
They all lower A1C by about 0.7% to 1%...reduce weight by 4 to 7 pounds...lower systolic BP by 3 to 5 mmHg...and rarely cause hypoglycemia.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote